Robert Holloway, MD
Gynecologic Oncology · Orlando, FLNPI 1538109137
Payments from drug & device makers
Across 814 payments — averaging $3818.66 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- GSK$774K
- Merck$576K
- F. Hoffmann-la Roche AG$412K
- Clovis Oncology, Inc.$367K
- Tesaro, Inc.$274K
- AbbVie$122K
- plus $583K from 29 others
Across 11 payments — averaging $191.88 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Regeneron$2K
- F. Hoffmann-la Roche AG$275
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| GSK | 160 | $774,068 |
| Merck | 65 | $576,345 |
| F. Hoffmann-la Roche AG | 39 | $412,338 |
| Clovis Oncology, Inc. | 64 | $366,535 |
| Tesaro, Inc. | 47 | $273,967 |
| AbbVie | 40 | $122,422 |
| Pharmaand GmbH | 15 | $74,175 |
| Sumitomo Pharma America, Inc. | 14 | $71,348 |
| Novocure Inc. | 14 | $66,929 |
| AstraZeneca | 38 | $57,160 |
| Springworks Therapeutics, Inc. | 55 | $54,713 |
| Genentech, Inc. | 27 | $51,543 |
| Davol Inc. | 18 | $37,303 |
| Eisai Inc. | 35 | $36,227 |
| Incyte Corporation | 88 | $34,402 |
| Karyopharm Therapeutics Inc. | 1 | $32,500 |
| Roche Products Limited | 1 | $18,800 |
| Hoffmann-la Roche Limited | 9 | $16,633 |
| Biom'up SA | 12 | $12,269 |
| Verastem, Inc. | 1 | $11,991 |
| Daiichi Sankyo Inc. | 3 | $1,663 |
| Intuitive Surgical | 43 | $1,585 |
| Seagen Inc. | 1 | $1,575 |
| Biom'up France SAS | 10 | $723 |
| Johnson & Johnson | 2 | $202 |
| Aadi Bioscience, Inc. | 2 | $158 |
| Conmed Corporation | 2 | $152 |
| Bayer | 1 | $125 |
| Tempus AI, Inc | 1 | $100 |
| Myriad Genetic Laboratories, Inc. | 1 | $97 |
| Caris MPI, Inc. | 1 | $89 |
| BD | 1 | $78 |
| Genentech USA, Inc. | 1 | $64 |
| Integra Lifesciences Corporation | 1 | $58 |
| Genmab U.S., Inc. | 1 | $51 |
How this compares
$3,108,389 in reported general payments places this provider in the 95th percentile of 117 gynecologic oncology providers in Florida.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Other gynecologic oncology in Orlando
- Shelly SewardOrlando$626K
- Nathalie McKenzieOrlando$229K
- Christopher BryantOrlando$51K
- Veronica SchimpOrlando$45K
- Jessica KennardOrlando$39K
- James KendrickOrlando$28K
- Lorna BrudieOrlando$15K
- Matthew SchlumbrechtMiami$16.7M
- Brian SlomovitzFort Lauderdale$13.9M
- Bradley MonkWest Palm Beach$10.5M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.